Ninerafaxstat在非梗阻性肥厚型心肌病中的代谢调节安全性与疗效
这项2期随机对照试验纳入67例非梗阻性肥厚型心肌病患者,评估新型心脏促代谢药ninerafaxstat 200 mg每日两次共12周的安全性与疗效。主要终点安全耐受性两组相似,ninerafaxstat显著改善通气效率(VE/Vco2斜率组间差-2.1,95%CI -3.6至-0.6,P=0.006),但峰值耗氧量无显著差异;在症状较重亚组中健康状态评分事后分析显著改善。
要点
- ninerafaxstat 200 mg每日两次共12周在非梗阻性肥厚型心肌病患者中安全可耐受。
- ninerafaxstat显著改善通气效率(VE/Vco2斜率),但峰值耗氧量无显著变化。
- 基线KCCQ-CSS≤80的患者事后分析中健康状态评分显著改善。
核心结论
- 在症状性非梗阻性肥厚型心肌病中,靶向心肌能量代谢的新药ninerafaxstat安全且耐受良好,并改善运动表现及症状较重患者的健康状态。
- 结果支持开展3期研究进一步评估ninerafaxstat。
研究设计与样本
- 随机、双盲、安慰剂对照2期试验,纳入左心室流出道压差<30 mmHg、射血分数≥50%、峰值耗氧量<80%预计值的肥厚型心肌病患者。
- 共67例患者随机接受ninerafaxstat 200 mg每日两次或安慰剂(1:1)治疗12周,来自12个中心,年龄57±11.8岁,女性占55%。
- 主要终点为安全性与耐受性,疗效终点为次要终点。
主要发现
- 严重不良事件发生率ninerafaxstat组为11.8%(4/34),安慰剂组为6.1%(2/33)。
- 12周时ninerafaxstat组VE/Vco2斜率较安慰剂组显著改善,组间最小二乘均值差为-2.1(95%CI -3.6至-0.6;P=0.006)。
- 峰值耗氧量组间无显著差异(P=0.90)。
- KCCQ临床总结评分在ninerafaxstat组有改善趋势但未达统计学显著(最小二乘均值3.2;95%CI -2.9至9.2;P=0.30)。
- 在基线KCCQ临床总结评分≤80的35例患者中事后分析显示KCCQ评分显著改善(最小二乘均值9.4;95%CI 0.3至18.5;P=0.04)。
临床怎么用
- 对于症状性非梗阻性肥厚型心肌病患者,ninerafaxstat可能改善通气效率和运动耐力,尤其适用于症状较重者,但需3期试验确认。
- 治疗期间应监测不良事件,该药总体安全耐受性良好。
局限性
- 本研究为2期试验,样本量较小(67例),疗效终点为次要终点。
- KCCQ评分的显著改善仅在基线KCCQ-CSS≤80的35例患者中事后分析得出,需谨慎解读。
- 研究期限较短(12周),长期安全性和疗效未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In nonobstructive hypertrophic cardiomyopathy (nHCM), there are no approved medical therapies. Impaired myocardial energetics is a potential cause of symptoms and exercise limitation. Ninerafaxstat, a novel cardiac mitotrope, enhances cardiac energetics. OBJECTIVES: This study sought to evaluate the safety and efficacy of ninerafaxstat in nHCM. METHODS: Patients with hypertrophic cardiomyopathy and left ventricular outflow tract gradient <30 mm Hg, ejection fraction ≥50%, and peak oxygen consumption <80% predicted were randomized to ninerafaxstat 200 mg twice daily or placebo (1:1) for 12 weeks. The primary endpoint was safety and tolerability, with efficacy outcomes also assessed as secondary endpoints. RESULTS: A total of 67 patients with nHCM were enrolled at 12 centers (57 ± 11.8 years of age; 55% women). Serious adverse events occurred in 11.8% (n = 4 of 34) in the ninerafaxstat group and 6.1% (n = 2 of 33) of patients in the placebo group. From baseline to 12 weeks, ninerafaxstat was associated with significantly better VE/Vco2 (ventilatory efficiency) slope compared with placebo with a least-squares (LS) mean difference between the groups of -2.1 (95% CI: -3.6 to -0.6; P = 0.006), with no significant difference in peak VO2 (P = 0.90). The Kansas City Cardiomyopathy Questionnaire Clinical Summary Score was directionally, though not significantly, improved with ninerafaxstat vs placebo (LS mean 3.2; 95% CI: -2.9 to 9.2; P = 0.30); however, it was statistically significant when analyzed post hoc in the 35 patients with baseline Kansas City Cardiomyopathy Questionnaire Clinical Summary Score ≤80 (LS mean 9.4; 95% CI: 0.3-18.5; P = 0.04). CONCLUSIONS: In symptomatic nHCM, novel drug therapy targeting myocardial energetics was safe and well tolerated and associated with better exercise performance and health status among those most symptomatically limited. The findings support assessing ninerafaxstat in a phase 3 study.
引用
- Maron MS, Mahmod M, Abd Samat AH, et al. Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024. PMID: 38599256. doi:10.1016/j.jacc.2024.03.387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。